ESPE2023

Thursday 21 September

07:00-20:00Registration
07:30-08:00Breakfast for Working Group Attendees
Pacific Foyer, King Willem Alexander on 1st Floor, First Floor Lobby, Amazon Foyeer
08:00-09:30ESPE Working Group on Disorders of Sex Development
Chair(s): Tülay Güran (Istanbul, Turkey)
Atlantic
08:00Introduction
08:05Case Presentation
08:15Case presentation
08:25Androgen insensitivity syndrome Type 1
08:50Androgen insensitivity syndrome Type 2
09:15Discussion with attendees
09:25Concluding Remarks
08:00-09:30ESPE Working Group on Obesity
Chair(s): Erica van den Akker (Rotterdam, The Netherlands)
Pacific
08:00The ESPE Obesity Working Group
08:20Environmental contributions to obesity development
08:40New treatment in children and adolescents with obesity
09:00Overweight and obesity in European Young Children: ToyBox-study lessons
09:20Q&A
08:00-09:30ESPE Bone and Growth Plate Working Group
Chair(s): Evelien Gevers (London, UK)
Yangtze 1&2
08:00Radiology of rare and less rare skeletal dysplasia
08:30Genetics of rare skeletal dysplasia
09:002x clinical case from working group members
08:00-09:30ESPE Working Group on Diabetes Technology
Chair(s): Moshe Phillip (Petah Tikva, Israel)
Mississippi
08:00Introduction
08:05Stage 1/Stage 2 T1DM – how do we monitor outside of clinical studies?
08:25CGM use in Stage 2 T1DM
08:45Immune intervention of newly diagnosed of T1DM – where are we today?
09:05Discussion - Round Table
08:00-09:30ESPE Working Group on Paediatric and Adolescent Gynaecology
Chair(s): Lourdes Ibanez Toda (Barcelona, Spain)
King Willem Alexander Auditorium
08:00Early puberty: connecting nutritional status and pubertal activation
08:25Environmental programming of early pubertal onset
08:50Management of early puberty : adaptation or overmedicalization?
08:00-09:30ESPE Working Group on Gender Incongruence
Chair(s): Sabine Hannema (Amsterdam, The Netherlands)
Amazon
08:00Gender dysphoria and autism, implications for diagnosis and decision making
08:30Animal models of transgender care, advantages and drawbacks
09:00Moral dilemmas surrounding puberty suppression in transgender adolescents’
08:00-09:30ESPE Working Group on Turner Syndrome
Chair(s): Janielle van der Velden (Nijmegen, The Netherlands)
Everest 1&2
08:00Challenges and opportunities in prenatal and postnatal diagnosis of Turner Syndrome & Parents’ Testimony
08:10Medical aspects
08:25Psychological aspects
08:35Ethical considerations
08:45Panel discussion (interactive)
09:15I-TS & pubertal induction study
09:25Update form TSWG and Disclosure
09:30-10:00Refreshment Break, Posters and Exhibition
Exhibition Hall
10:00-10:15Opening Ceremony
King Willem Alexander Auditorium
10:15-10:45Plenary 1: Sex Differences in the Brain: Intersection of the Endocrine, Immune and Nervous Systems
Chair(s): Anita Hokken-Koelega (Rotterdam, The Netherlands) & Sabine Hannema (Amsterdam, The Netherlands)
King Willem Alexander Auditorium
10:15PL1Sex Differences in the Brain: Intersection of the Endocrine, Immune and Nervous Systems
10:45-11:15Awards 1 - Henning Andersen Prizes
Chair(s): Nils Krone (Sheffield, UK)
King Willem Alexander Auditorium
10:45Awards 1 - Henning Andersen Prizes
11:25-12:55Symposium 1 - Disorders of Sex Development
Chair(s): Angela Lucas Herald (Glasgow, UK) & David Zangen (Jerusalem, Israel)
Atlantic
11:25S1.1Life-long care for people with 46,XY DSD
11:55S1.2Regulation of germ cell fate during sex determination
12:25S1.3Pathogenesis of testicular dysfunction in Klinefelter syndrome
11:25-12:55Symposium 2 - Hypothalamo-pituitary disorders
Chair(s): Mariacarolina Salerno (Naples, Italy) & Roland Pfaffle (Leipzig, Germany)
Pacific
11:25S2.1Novel imaging techniques in pituitary tumours
11:55S2.2Stem cells in the pituitary
12:25S2.3Pioneer transcription factors
11:25-12:55Symposium 3 - Endocrine effects of cancer treatment
Chair(s): Hoong-wei Gan (London, UK) & Hanneke van Santen (Utrecht, The Netherlands)
Mississippi
11:25S3.1Safety of GH treatment in cancer survivors
11:55S3.2Surveillance for endocrine disease in Childhood Cancer Survivors
12:25S3.3Fertility preservation in children with cancer
11:25-12:55Symposium 4 - Novel insights and innovations in diabetes
Chair(s): Jacques Beltrand (Paris, France) & May Ng (Liverpool, UK)
Yangtze 1&2
11:25S4.1Role of alpha cells in islet function
11:55S4.2Delaying the development of T1DM
12:25S4.3Physical interaction between beta and delta cells
11:25-12:25Yearbook 1
Chair(s): Christa Flück (Bern, Switzerland)
Amazon
11:25YB1.1Global Health for the Paediatric Endocrinologist
11:37YB1.2Type 2 Diabetes, Metabolic Syndrome and Lipids
11:49YB1.3Obesity and Weight Regulation
12:01YB1.4Adrenal
12:13YB1.5The Year in Science & Medicine
12:55-14:25Lunch, posters and exhibition
Exhibition Hall
13:15-14:15 Satellite Symposium 1
For more information please see satellite programme
13:15-14:15Satellite Symposium 2
For more information please see satellite programme
14:25-15:55How do I…? 1
Chair(s): Naomi Weintrob (Tel Aviv, Israel) & Johnny Deladoëy (Montréal, Canada)
King Willem Alexander Auditorium
14:25HDI1.1How do I manage abnormal thyroid function tests in the newborn?
14:55HDI1.2How do I use AMH in paediatric practice?
15:25HDI1.3How do I manage a child with hypercalcemia?
14:25-14:55Rapid Free Communications 1: Adrenals and HPA Axis
Chair(s): Christa Flück (Bern, Switzerland) & Li Chan (London, UK)
Pacific
14:25RFC1.4Unfavorable Body Composition in Children with Premature Adrenarche: Implications for Metabolic Health
14:30RFC1.3The chimeric CYP21A1P/CYP21A2 and TNXA/TNXB gene deficiencies in patients with Congenital Adrenal Hyperplasia
14:35RFC1.5The effect of storage and temperature on the stability of steroid hormones in dried blood spots
14:40RFC1.1Lack of NAD(P)+ transhydrogenase activity in patients with primary adrenal insufficiency due to NNT mutations
14:45Clinical and genetic characteristics of 42 Chinese paediatric patients with X-Linked Adrenal Hypoplasia Congenita
14:50RFC1.2Interlaboratory comparison of LC-MS/MS measurements of 11 relevant steroid hormones in 27 DSD patients
14:25-14:55Rapid Free Communications 2: Bone, growth plate and mineral metabolism
Chair(s): Evelien Gevers (London, UK) & Wolfgang Högler (Linz, Austria)
Mississippi
14:25RFC2.1Identification of novel genes including NAV2 associated with isolated tall stature
14:30RFC2.2Familial pseudohypoparathyroidism type IB associated with an SVA retrotransposon insertion in the GNAS locus.
14:35RFC2.3High incidence of Chiari type I anomalies on MRI in young patients with X-linked hypophosphatemic rickets (XLHR)
14:40RFC2.4Documentation of inactivating PTH/PTHrP Signaling Disorders (Pseudohypoparathyroidism) cases in EuRRECa / EuRR-Bone: a challenging, but worthwhile journey
14:45RFC2.5Growth in young children with X-linked hypophosphatemia treated with burosumab
14:50RFC2.6Short term side effects of first bisphosphonate infusion in children with different underlying bone pathologies.
14:25-14:55Rapid Free Communications 3: Fat, metabolism and obesity 1
Chair(s): Francesco Chiarelli (Chieti, Italy) & Senthil Senniappan (Liverpool, UK)
Yangtze 1&2
14:25RFC3.1Fasting and meal-related zonulin serum levels in a large cohort of obese children and adolescents: a cross sectional study
14:30RFC3.2Reduced central sensitivity to thyroid hormones in children and adolescents with overweight or obesity and impaired glucose tolerance.
14:35RFC3.3Early Corneal Nerve Loss in Children with Melanocortin 4 Receptor (MC4R) Gene Mutation Related Obesity
14:40RFC3.4Effect of maternal diet and breastfeeding on growth and distribution of adiposity from birth up to 12 months: data from the European LIFE-MILCH project
14:45RFC3.5Multi-omics Reveals molecule target Underlying Adolescent obesity with metabolic syndrome
14:50RFC3.6Glucocorticoid-mediated leptin secretion from human adipocytes is dependent on glucose availability
14:25-14:55Rapid Free Communications 4: Growth and syndromes (to include Turner syndrome)
Chair(s): Cheri Deal (Montréal, Canada) & Janielle van der velden (Nijmegen, The Netherlands)
Atlantic
14:25RFC4.1Functional networks reveal pathways linking early growth to childhood blood pressure in the Manchester BabyGRO Study
14:30RFC4.2Molecular genetic diagnosis in children with Idiopathic Short Stature: Single Center Experience
14:35RFC4.3Aromatase inhibitors: an effective and safe option for height increment in boys with growth hormone deficiency?
14:40RFC4.4Genetic findings in short Turkish children born to consanguineous parents
14:45RFC4.5Real-world safety and effectiveness of vosoritide: Results from an early access program in France
14:50RFC4.6Results from the PROPEL 2 dose-finding study: oral infigratinib leads to significant increases in height velocity with good tolerability in children with achondroplasia
14:25-14:55Rapid Free Communications 5: Diabetes and insulin 1
Chair(s): Paul Voorhoeve (Nijmegen, The Netherlands) & Marianna Rachmiel (Zerifin, Israel)
Amazon
14:25RFC5.1Tear proteomics profile in children and adolescents with type 1 diabetes mellitus
14:30RFC5.2Comparison of Optical Coherence Tomography Angiography Findings in Children with Type 1 Diabetes Mellitus and Autoimmune Thyroiditis with Healthy Children
14:35RFC5.33 Screen ICA ELISA–A new tool to identify pre-clinical diabetes in first-degree relatives of patients with type 1 diabetes (pre-d1abetes study)
14:40RFC5.4Effect of probiotic on glycemic control in children with type 1 diabetes : A randomized controlled trial
14:45RFC5.5Syndrome of hypoglycemia unawareness in children with type 1 diabetes: clinical contribution of Clark and Gold questionnaire
14:50RFC5.6Do females with Type 1 Diabetes have puberty earlier?
14:55-15:55Free Communications 1: Adrenals and HPA Axis
Chair(s): Christa Flück (Bern, Switzerland) & Li Chan (London, UK)
Pacific
14:55FC1.1Investigating intergenerational effects of glucocorticoids
15:05FC1.2The pathophysiologic response of central nervous system due to differently impaired steroidogenesis
15:15FC1.4Response to Crinecerfont Treatment in Adolescents with Classic Congenital Adrenal Hyperplasia Is Correlated with Elevated Baseline Hormone Concentrations but Not Glucocorticoid Dose
15:25FC1.3Generation and Characterization of a novel Humanized CYP21A2 Knock-in Mouse Model for Congenital Adrenal Hyperplasia
15:35FC1.5Management of congenital adrenal hyperplasia in the first 90 days of life: a multi-centre I-CAH analysis of contemporary practice
15:45FC1.6Cardiovascular risk profile in adult patients with congenital adrenal hyperplasia: a cross-sectional study
14:55-15:55Free Communications 2: Bone, growth plate and mineral metabolism
Chair(s): Evelien Gevers (London, UK) & Wolfgang Högler (Linz, Austria)
Mississippi
14:55FC2.1Hearing loss in pseudohypoparathyroidism (inactivating PTH/PTHRP Signaling Disorder): a prospective study to assess prevalence and predictive factors of hearing loss in 44 patients affected with iPPSD/PHP
15:05FC2.2First Results of the Global ALPL Gene Variant Classification Project
15:15FC2.3Hyperparathyroidism after three years of burosumab in children affected with x-linked hypophosphatemia
15:25FC2.4A real-world study in Germany and Switzerland regarding renal health in children with X-linked hypophosphatemia
15:35FC2.5Generation of novel genetic zebrafish models and using RNA-seq analysis to explore the role of ankrd11 gene on bone growth
15:45FC2.6Human breast milk-derived exosomes promote growth plate cell lines in vitro
14:55-15:55Free Communications 3: Fat, metabolism and obesity 1
Chair(s): Francesco Chiarelli (Chieti, Italy) & Senthil Senniappan (Liverpool, UK)
Yangtze 1&2
14:55FC3.1Early childhood height and weight development in children with monogenic obesity: A European multicenter cohort study
15:05FC3.2Analysis of ligand- and mutation-dependent signaling of the melanocortin 4 receptor (MC4R): an example of the relevance of differential signaling (bias signaling)
15:15FC3.3Frequency of Obesity-Related Gene Variants in a European Population With Early-Onset, Severe Obesity
15:25FC3.4A Novel Mutation in DYRK1B Associated With Abdominal Obesity Metabolic Syndrome 3 (AOMS3)
15:35FC3.5Early corneal nerve loss in children with obesity and type 2 diabetes
15:45FC3.6Impact of Setmelanotide on Future Metabolic Syndrome Risk in Pediatric Patients With Bardet-Biedl Syndrome
14:55-15:55Free Communications 4: Growth and syndromes (to include Turner syndrome)
Chair(s): Cheri Deal (Montréal, Canada) & Janielle van der velden (Nijmegen, The Netherlands)
Atlantic
14:55FC4.1Heterozygous Null Mutations in FLNB as a Cause of apparent isolated Short Stature in Chinese Children
15:05FC4.2Genetic and phenotypic features of children with familial tall stature
15:15Pathogenic variants in GHSR cause short stature and growth hormone neurosecretory dysfunction; results from a large case series
15:25Growth failure in aggrecan haploinsufficiency is due to a decrease in growth plate matrix volume and hypertrophic cell size
15:35From thalidomide embryopathy to genetic defects of the upper limb, internal organs, cerebral midline, and pituitary: The phenotypic spectrum of SALL4
15:45Persistence of Growth Promoting Effects in Infants and Toddlers with Achondroplasia: Results in Children Aged Over 2 Years Old from a Phase II Extension Study with Vosoritide
14:55-15:55Free Communications 5: Diabetes and insulin 1
Chair(s): Paul Voorhoeve (Nijmegen, The Netherlands) & Marianna Rachmiel (Zerifin, Israel)
Amazon
14:55FC5.1Diabetes mellitus and gender incongruence: Worse metabolic control in type 1 and higher mental health issue rates in type 1 and 2 diabetes – a DPV registry study
15:05FC5.2Nailfold capillaroscopy: An alternative non-invasive tool for evaluating microvascular involvement in children with type 1 diabetes
15:15FC5.3How feasible is it to meet the Time in Tight Range (TITR) target with Automatic Insulin Delivery (AID)?: 2128-day real-world data from a single center
15:25FC5.4Changes of intestinal flora in children with type 1 diabetes mellitus and its related immune mechanism
15:35FC5.5Sleep Characteristics, Glycemic Control, and Endothelial Function in Adolescents and Young Adults with Type 1 Diabetes
15:45FC5.6Post-Hypoglycemic Hyperglycemia Are Highly Relevant Markers For Stratification Of Glycemic Variability and Remission Status Of Pediatric Patients With New-Onset Type 1 Diabetes.
15:55-16:15Refreshment Break, Posters and Exhibition
Exhibition Hall
16:15-16:45Plenary 2
Chair(s): Stefano Cianfarani (Rome, Italy) & Erica van den Akker (Rotterdam, The Netherlands)
King Willem Alexander Auditorium
16:15PL2The food environment and the global childhood obesity epidemic: The role of ultra-processed food
16:55-17:40Meet the Expert 1.1
Mississippi
16:55Management of MEN1 in children and adolescents
16:55-17:40Meet the Expert 2.1
Atlantic
16:55Informing children about their DSD – when and how?
16:55-17:40Meet the Expert 3.1
Yangtze 1&2
16:55Uncertainties around diagnosing growth hormone deficiency
16:55-17:40Meet the Expert 4.1
Amazon
16:55Clinical Management of Prader-Willi Syndrome in infants, children and adolescents
16:55-17:55Ethics in Endocrinology
Chair(s): Theo Sas (Rotterdam, The Netherlands) & Marek Niedziela (Poznan, Poland)
King Willem Alexander Auditorium
16:55EE1.1Ethics of expensive treatments
17:25EE1.2Should we strive for normality?
17:50-19:20 Satellite Symposium 3
For more information please see satellite programme
17:50-19:20Satellite Symposium 4
For more information please see satellite programme
17:50-19:20Satellite Symposium 5
For more information please see satellite programme

Friday 22 September

07:15-19:30Registration
08:00-08:30Plenary 3
Chair(s): Agnès Linglart (Paris, France) & Paul van Trotsenburg (Amsterdam, The Netherlands)
King Willem Alexander Auditorium
08:00PL3Structural and functional development of the adolescent brain
08:15-08:45Industry Expert Forum 1
For more information please see Industry Expert programme
08:30-09:30Controversy 1
Chair(s): Peter Clayton (Manchester, UK) & Philippe Backeljauw (Cincinnati, USA)
King Willem Alexander Auditorium
08:30Pharmacological manipulation of bone maturation should be used to preserve final height in short children (FOR)
08:30Pharmacological manipulation of bone maturation should NOT be used to preserve final height in short children (AGAINST)."
08:35-09:20Meet the Expert 5.1
Yangtze 1&2
08:35Management of Pituitary adenomas in Children
08:35-09:20Meet the Expert 6.1
Atlantic
08:35Approach to Thyroid cancer in Children
08:35-09:20Meet the Expert 7.1
Amazon
08:35Management of hyperinsulism beyond the acute phase
08:35-09:20Meet the Expert 8.1
Mississippi
08:35 Puberty induction in hypogonadism
08:35-09:20Meet the Expert 1.2
Pacific
08:35Management of MEN1 in children and adolescents
09:00-09:30Industry Expert Fora 2&3
For more information please see Industry Expert programme
09:30-11:00Endo-ERN Symposium
Chair(s): Olaf Hiort (Lübeck, Germany) & Luca Persani (Milan, Italy)
Oceania
09:30Perspective of Endo-ERN for the next five years
09:40European medicine shortages: How can we avoid a disaster for patients with rare conditions?
10:05It matters - set up of clinical trials in rare diseases
10:35ERNs and clinical trials; the ERICA and Rare Disease Partnership perspective
09:30-10:00Rapid Free Communications 6: Pituitary, neuroendocrinology and puberty 1
Chair(s): Nitash Zwaveling-Soonawala (Amsterdam, The Netherlands) & Paul Dimitri (Sheffield, UK)
Pacific
09:30RFC6.1Clinical application of LH cut-off value in the diagnosis of CPP according to the international consensus
09:35RFC6.2Psychosocial Evaluation of Girls with Rapidly Progressive Puberty Presenting with Early Menarche
09:40RFC6.3Exposure to Per- and Polyfluoroalkyl Substances and Pubertal Assessment by Ultrasound in Norwegian Boys and Girls: Data from the Bergen Growth Study 2
09:45RFC6.4Earlier Occurrence of Puberty and Pubertal Hair Development in Boys and Girls - Insights from the DPV Initiative Data
09:50RFC6.5EFFICACY AND SECURITY OF GONADOTROPIN TREATMENT IN ADOLESCENTS WITH CONGENITAL HYPOGONADOTROPIC HYPOGONADISM
09:55RFC6.6Evaluation of Serum MKRN3 and DLK1 Concentrations for Predicting Variant Detection in MKRN3 and DLK1Genes in Patients with Central Precocious Puberty
09:30-10:00Rapid Free Communications 7: Sex differentiation, gonads and gynaecology or sex endocrinology
Chair(s): Hedi Claahsen (Nijmegen, The Netherlands) & Anna Nordenström (Stockholm, Sweden)
Atlantic
09:30RFC7.1Penile width increases more clearly than penile length during minipuberty: a longitudinal study of 136 healthy infant boys
09:35RFC7.2International Evidence-Based Guidelines for PCOS 2023: Recommendations in Adolescent Girls
09:40RFC7.3Histone code, cryptorchidism,infertility
09:45RFC7.4Serum steroid metabolome dynamics during infancy: a prospective, longitudinal cohort of healthy boys
09:50RFC7.5Sex differences in endocrine mechanisms during early human fetal brain development
09:55RFC7.6Prenatal AnoGenital Distance (AGD) by ultrasonography in 571 fetuses and correlation to postnatal AGD: A longitudinal cohort study of healthy males and females
09:30-10:00Rapid Free Communications 8: Fat, metabolism and obesity 2
Chair(s): Cosimo Giannini (Chieti, Italy) & Thomas Reinehr (Datteln, Germany)
Yangtze 1&2
09:30RFC8.1A novel heterozygous likely pathogenic variant in GNB1 causing hyperphagia, severe early onset obesity and neurodevelopmental disorder
09:35RFC8.2Acute rise of leptin after five days of dexamethasone and its association with hunger, fat mass, sleep and fatigue, in children with acute lymphoblastic leukemia
09:40RFC8.3Higher levels of serum α-Klotho are longitudinally associated with less visceral fat accumulation in apparently healthy girls experiencing weight gain
09:45RFC8.4Understanding the genetics of early onset obesity in a cohort of children from Qatar
09:50RFC8.5Effects of leptin knockdown on a human preadipocyte model
09:55RFC8.6Leukocytes and Neutrophil–Lymphocyte Ratio as Indicators of decreased insulin sensitivity in NGT Overweight and Obese Children with high 1-hour post-load plasma glucose levels
09:30-10:00Rapid Free Communications 9: Diabetes and insulin 2
Chair(s): Kanetee Busiah (Vaud, Switzerland) & Mieke Houdijk (Leiden, The Netherlands)
Mississippi
09:30RFC9.1The association of dietary glycemic index and load with insulin sensitivity and secretion from early childhood to late adolescence: the QUALITY cohort
09:35RFC9.2Two new candidate genes,OGDH and FGFR1 discovered in an insulinoma from a fifteen-year-old male
09:40RFC9.3Impaired Insulin Secretion as a Pathophysiology Underlying Abnormal Glucose Metabolism in Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors: A Study Comparing Glucose Metabolism between ALL Survivors and Simple Obese Children
09:45RFC9.4Clinical and genetic characteristics of patients suspected to have Maturity-Onset Diabetes of the Young in the Czech Republic
09:50RFC9.5Insulin secretion defect in children and adolescents with obesity: Clinical and molecular genetic characterization
09:55RFC9.6Wharton jelly derived mesenchymal stem cells exosomes protect pancreatic beta cells from inflamation
09:30-10:00Rapid Free Communications 10: Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) & Multisystem endocrine disorders
Chair(s): Rasa Verkauskiene (Kaunas, Lithuania) & Martijn Finken (Amsterdam, The Netherlands)
Amazon
09:30RFC10.1A novel maternally inherited GNAS variant in a family with hyperphagia and obesity.
09:35RFC10.2Utility of Continuous Glucose Monitoring (CGM) during pancreatic surgery in patients with Congenital Hyperinsulinism
09:40RFC10.3Non-coding Variants in HK1 Account for 5% of Cases of Congenital Hyperinsulinism Without an Identified Genetic Cause
09:45RFC10.4Clinical phenotypes of a multicentric cohort of ROHHAD patients
09:50RFC10.5Insulinoma in childhood: A multicenter retrospective study of 28 patients
09:55RFC10.6Two novel mutations in the DCAF17 gene in two Palestinian families with primary amenorrhea revealing molecular genetics in Woodhouse-Sakati syndrome & unique presentation
10:00-11:00Free Communications 6: Pituitary, neuroendocrinology and puberty 1
Chair(s): Nitash Zwaveling-Soonawala (Amsterdam, The Netherlands) & Paul Dimitri (Sheffield, UK)
Pacific
10:00FC6.1Methylome analysis in idiopathic central precocious puberty girls
10:10FC6.2The role of body composition and appetite-regulating hormones in idiopathic central precocious puberty and their changes during GnRH analogue therapy.
10:20FC6.3Is the 24-hour urinary gonadotropin assay an effective diagnostic tool in central precocious puberty? A retrospective study of threshold setting and validation in two cohorts.
10:30FC6.4Sleeptime-excreted total urinary luteinizing hormone concentrations reveal that the onset of central puberty occurs at around the same time in boys and girls: a longitudinal study
10:40FC6.5Clinical characteristics of 213 children with early pubertal development complicated with pineal cyst
10:50FC6.6Serum Kisspeptin and DLK1 levels as a tool for diagnosis and monitoring of central precocious puberty treatment in Thai girls
10:00-11:00Free Communications 7: Sex differentiation, gonads and gynaecology or sex endocrinology
Chair(s): Hedi Claahsen (Nijmegen, The Netherlands) & Anna Nordenström (Stockholm, Sweden)
Atlantic
10:00FC7.1Polygenic scores for testosterone and SHBG are associated with hormone levels in male infants
10:10FC7.2Mapping the transcriptomic landscape of early human fetal ovary development through a clinically-focused lens
10:20FC7.3ROS scavengers may improve genital skin healing in boys with hypospadias
10:30FC7.4The effect of common genetic variants in CYP19A1 on serum Estradiol to Testosterone Ratio in healthy Danish children and adolescents
10:40FC7.5SGPL1 deficiency, a cause of 46XY DSD and adrenal insufficiency, impairs lipid metabolism and steroidogenesis in Leydig cells
10:50FC7.6GnRHa response patterns of testis expressed genes in cryptorchid boys
10:00-11:00Free Communications 8: Fat, metabolism and obesity 2
Chair(s): Cosimo Giannini (Chieti, Italy) & Thomas Reinehr (Datteln, Germany)
Yangtze 1&2
10:00FC8.1Aberrant expression of agouti signaling protein (ASIP) as a new cause of monogenic severe childhood obesity
10:10FC8.2Frequency of MC4R Pathway Variants in a European Cohort of Individuals With Early-Onset Severe Obesity
10:20FC8.3Impact of growth hormone therapy on body mass index in childhood-onset craniopharyngioma: a multicenter Italian study in 117 patients.
10:30FC8.4Irs1 expression in peripheral blood associates with obesity and cardiovascular risk parameters in school-age girls
10:40FC8.5Impact of Setmelanotide on Metabolic Syndrome Risk in Pediatric Patients With POMC and LEPR Deficiency
10:50FC8.6Liraglutide treatment in adolescents with extreme obesity - Effects on weight loss in the first 9 months under real-life conditions
10:00-11:00Free Communications 9: Diabetes and insulin 2
Chair(s): Kanetee Busiah (Vaud, Switzerland) & Mieke Houdijk (Leiden, The Netherlands)
Mississippi
10:00FC9.1Reference values for the insulin response to glucose challenge enable the early detection of emerging (pre)diabetes in children and young adults with obesity
10:10FC9.2Characterization of pediatric patients with type 2 diabetes and trends in their pharmaceutical management 2000-2022 in German-speaking countries: Analysis based on the DPV registry
10:20FC9.3A novel case of hypoglycaemia secondary to a pro-insulin processing disorder
10:30FC9.4The high proportion of INS-MODY in Chinese children with MODY
10:40FC9.5A case of NARS1 deficiency resulting in diabetes mellitus with liver cirrhosis and pancreatic atrophy
10:50FC9.6Puberty and Gonadal function in Wolfram Syndrome: A retrospective single centre study
10:00-11:00Free Communications 10: Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) & Multisystem endocrine disorders
Chair(s): Rasa Verkauskiene (Kaunas, Lithuania) & Martijn Finken (Amsterdam, The Netherlands)
Amazon
10:00FC10.1Dasiglucagon safety in paediatric participants with CHI
10:10FC10.2Immune profile response to rituximab in ROHHAD syndrome
10:20FC10.3ROHHAD syndrome, thrombotic risk and endothelial damage: a single center experience.
10:30FC10.4A Novel Mutation in RAI1 Gene in a Patient with Clinical Diagnosis of Rapid-Onset Obesity with Hypothalamic Dysregulation, Hypoventilation, and Autonomic Dysregulation (ROHHAD) Syndrome with Overlapping Symptoms of Smith Magenis Syndrome (SMS).
10:40FC10.5MCM4 deficiency causing Natural Killer and Glucocorticoid Deficiency with DNA repair defect (AR-NKGCD) - a large cases series from the Irish Traveller Community
10:50FC10.6PLACENTAL MEST GENE EXPRESSION IS ASSOCIATED WITH POSTNATAL GROWTH AND OBESITY
11:00-11:30Refreshment Break, Posters and Exhibition
Exhibition Hall
11:30-12:00Awards 2
ESPE Research Award
Chair(s): Agnès Linglart (Paris, France)
King Willem Alexander Auditorium
11:30ESPE Research Award
12:00-12:30Plenary 4
Chair(s): Martine Cools (Ghent, Belgium) & Faisal Ahmed (Glasgow, UK)
King Willem Alexander Auditorium
12:00 How AI will change medicine
12:30-13:00Awards 3
King Willem Alexander Auditorium
ESPE International Outstanding Clinician Award
Outstanding Clinician Award
ESPE Hormone Research in Paediatrics Prizes
IFCAH-ESPE Award
13:00-14:30Lunch, posters and exhibition
Exhibition Hall
13:20-14:20Satellite Symposium 5
For more information please see satellite programme
14:30-15:30Yearbook 2
Chair(s): Ken Ong (Cambridge, UK)
Amazon
14:30YB2.1Puberty
14:42YB2.2DSD and gender incongruence
14:54YB2.3Oncology and Chronic Disease
15:06YB2.4Diabetes Type 1
15:18YB2.5Editors' Choice
14:30-16:00Symposium 5 - Hypothalamic syndromes
Chair(s): Herman Müller (Berlin, Germany) & Maithé Tauber (Toulouse, France)
Mississippi
14:30S5.1Hypothalamic syndrome in Cancer survivors
15:00S5.2The evolution of the hypothalamus
15:30S5.3ROHHAD/ROHHADNET syndrome
13:20-14:20 Satellite Symposium 6
For more information please see satellite programme
13:20-14:20 Satellite Symposium 7
For more information please see satellite programme
14:30-16:00Symposium 6 - Neonatal endocrinology
Chair(s): Khalid Hussain (Doha, Qatar) & Maria Güemes (Madrid, Spain)
Yangtze 1&2
14:30S6.1Unravelling the role of epigenetics in reproductive adaptations to early-life environment
15:00S6.2The role of insulin in prenatal programming of future metabolic disease
15:30S6.3The development of the HPA axis of the newborn
14:30-16:00Symposium 7 - Theories of obesity development and their implications on dietary interventions
Chair(s): Violeta Iotova (Varna, Bulgaria) & Ram Weiss (Jerusalem, Israel)
Pacific
14:30S7.1Competing Paradigms of Obesity Pathogenesis
15:00S7.2From the social life through the psyche and the brain to the epidemic expansion of the adipose mass
15:30S7.3Polygenic risk score
14:30-16:00Symposium 8 - Adrenals
Chair(s): Evangelia Charmandari (Athens, Greece) & Uta Neumann (Berlin, Germany)
Atlantic
14:30S8.1Understanding the role of 11-oxygenated androgens
15:00S8.2Adrenal cortex renewal in health and disease
15:30S8.3Central nervous consequences of CAH and other adrenal disorders
14:30-16:00ESPE Nursing and Allied Health Working Group (PENS)
Chair(s): Camilla Ernstsson (Umeå, Sweden), Clare Simpson (Leeds, UK) & Sandra Greetham (Hull, UK)
Everest 1&2
14:30Childhood craniopharyngioma - challenges for the pediatric endocrinologist
15:00The role of a nurse in managing and supporting children and their families with a craniopharyngioma - Roisin Boyle
15:30Q&A in Endocrine Nursing
16:10-16:40Plenary 5
Chair(s): Rasha Hamza (Cairo, Egypt) & Mehul Dattani (London, UK)
King Willem Alexander Auditorium
16:10PL5Cracking the pituitary stem cell code across life using single-cell transcriptomics and organoid models
16:40-17:00Refreshment Break, Posters and Exhibition
Exhibition Hall
17:00-18:30 Satellite Symposium 8
For more information please see satellite programme
17:00-18:30Satellite Symposium 9
For more information please see satellite programme
17:00-18:30Satellite Symposium 10
For more information please see satellite programme
18:30-19:45ESPE Annual Business Meeting
Pacific

Saturday 23 September

07:15-18:30Registration
08:00-08:45Meet the Expert 3.2
Yangtze 1&2
08:00Uncertainties around diagnosing growth hormone deficiency
08:00-08:45Meet the Expert 4.2
Pacific
08:00Clinical Management of Prader-Willi Syndrome in infants, children and adolescents
08:00-08:45Meet the Expert 5.2
Everest 1&2
08:00Management of Pituitary adenomas in Children
08:00-08:45Meet the Expert 8.2
Atlantic
08:00Puberty induction in hypogonadism
08:00-09:00Yearbook 3
Chair(s): Christa Flück (Bern, Switzerland) & Ken Ong (Cambridge, UK)
Amazon
08:00YB3.1Thyroid
08:15YB3.2Growth and Growth Factors
08:30YB3.3Bone, Growth Plate and Mineral Metabolism
08:45YB3.4A tribute to Ze’ev Hochberg’s work
09:00-10:30How do I…? 2
Chair(s): Zdenek Sumnik (Prague, Czech Republic) & Saartje Straetemans (Maastricht, The Netherlands)
King Willem Alexander Auditorium
09:00HDI2.1How to manage long term complications in T2DM in adolescents?
09:30HDI2.2How Do I initiate and follow patients on a closed-loop system?
10:00HDI2.3Diagnosis and management of hypercholesterolemia
09:00-09:30Rapid Free Communications 11: GH and IGFs
Chair(s): Helen Storr (London, UK) & Christiaan de Bruin (Leiden, The Netherlands)
Pacific
09:00RFC11.1The genetic aetiology of primary multiple pituitary hormone deficiency: a next-generation sequencing analysis of a single-centre cohort.
09:05RFC11.2Are pappalysins and stanniocalcins involved in modifying the bioavailability of IGF-I in children with onset of type 1 diabetes mellitus?
09:10RFC11.3Longitudinal assessment of health-related quality of life (HRQoL) & behavior in adults born small for gestational age (SGA) who were treated with growth hormone during childhood
09:15RFC11.4Functional analysis of a novel mutation of IGF1R gene in two twins with growth failure. An example of genotype-phenotype heterogeneity.
09:20RFC11.5Influence of sirtuin 1 and fibroblast growth factor 21 levels on IGF-1 concentration in children with short stature of different etiology
09:25RFC11.6Evaluation Of The Growth Hormone-Insulin like Growth Factor1 Axis And Serum Fibroblast Growth Factor 21 Levels As Related To Stature In Children And Adolescents With Coeliac Disease Adherent To Gluten Free Diet
09:00-09:30Rapid Free Communications 12: Thyroid
Chair(s): Athanasia Stoupa (Paris, France) & Joachim Pohlenz (Mainz, Germany)
Mississippi
09:00RFC12.1Macro-TSH IgG complex in a case of Congenital Hypothyroidism (CH).
09:05RFC12.2A novel frameshift mutation in Immunoglobulin Superfamily, Member 1 (IGSF1) causing central hypothyroidism, delayed puberty and GH deficiency
09:10RFC12.3Thyroid disorders in childhood cancer survivors treated with 131 I-MIBG, TKIs or immune checkpoint inhibitors: incidence, mechanisms and clinical management – systematic review
09:15RFC12.4Polyethylene glycol thyroid stimulating hormone (PEG-TSH) in real-life: a practical tool for solving a biochemical dilemma
09:20RFC12.5Application of Shear Wave Elastography (SWE) in the ultrasound evaluation of thyroid nodules in children and adolescents
09:25RFC12.6Phenylbutyrate treatment of three patients with Monocarboxylate Transporter 8 deficiency
09:00-09:30Rapid Free Communications 13: Pituitary, neuroendocrinology and puberty 2
Chair(s): Cynthia Andoniadou (London, UK) & Anne Rochtus (Leuven, Belgium)
Atlantic
09:00RFC13.1Are Glucagon-like peptide-1 (GLP-1) receptor agonists a new treatment option for hypothalamic obesity in the paediatric population: Preliminary experience from a tertiary paediatric endocrine centre
09:05RFC13.2Arginine-stimulated copeptin is independent of GH secretion status
09:10RFC13.3Treatment and outcome of the Dutch Childhood Craniopharyngioma Cohort study; first results after centralization of care
09:15RFC13.4Trio analyses of patients with congenital hypopituitarism reveals novel candidate genes
09:20RFC13.5Growth hormone and TSH deficiency after [177Lu]Lu-DOTATATE therapy for pediatric neuroblastoma; description of a first case.
09:25RFC13.6Pituitary size on volumetric MRI predicts the severity of the neuroendocrine phenotype in populations at risk
09:00-09:30Rapid Free Communications 14 - Late Breaking
Chair(s): Annemarie Verrijn-Stuart (Utrecht, Netherlands) & Tommaso Aversa (Messina, Italy)
Yangtze 1&2
09:00RFC14.1Clinical characteristics of patients presented with primary adrenal insufficiency due to a p.R451W mutation in the CYP11A1 gene
09:05RFC14.2No Relationship Between Thyroid Function and ADHD – Results From a Nationwide Prospective Epidemiological Study and Mendelian Randomization
09:10RFC14.3Body composition in a pediatric population with type 1 diabetes mellitus - The importance of planned physical activity
09:15RFC14.4Evaluating the Effect of Recombinant Human Growth Hormone Treatment on Sleep-related Breathing Disorders in Toddlers with Prader–Willi Syndrome: a one-year retrospective cohort study.
09:20RFC14.5Functional demonstration that variants in the C-terminal of IHH cause short stature and/brachdactyly
09:25RFC14.6Enhanced histones acetylation in children with obesity: relationship with insulin resistance and inflammation
09:30-10:30Free Communications 11: GH and IGFs
Chair(s): Helen Storr (London, UK) & Christiaan de Bruin (Leiden, The Netherlands)
Pacific
09:30FC11.1GH replacement therapy with once-weekly somapacitan in children with GH deficiency is effective and well-tolerated: 2-year results from REAL4
09:40FC11.2Clinical characteristics of heterozygous ACAN gene variants and longer-term response to growth hormone treatment: real-world data
09:50FC11.3Analysis of a large panel of genes in a cohort of patients with severe short stature: detection rate and genotype-phenotype correlations
10:00FC11.4Long-term GH-treatment of children born small for gestational age (SGA) does not result in cerebrovascular abnormalities in adulthood compared to untreated controls
10:10FC11.5Effective GH Replacement with Once-weekly Somapacitan in Japanese Children with GH Deficiency: 2-year Results from REAL4
10:20FC11.6Longitudinal analysis of the risk of brain tumour recurrence or progression in relation to the timing of commencement of growth hormone replacement therapy.
09:30-10:30Free Communications 12: Thyroid
Chair(s): Juliane Leger (Paris, France) & Joachim Pohlenz (Mainz, Germany)
Mississippi
09:30FC12.1Graves’ disease – are we just delaying the inevitable?
09:40FC12.2Thyroid function analysis in 48 patients affected by severe combined immunodeficiency caused by adenosine deaminase deficiency
09:50FC12.3Hypothyroidism due to IYD bi-allelic pathogenic variants: clinical description of eight patients
10:00FC12.4Thyroid hormone resistance due to THRB gene mutations : neonatal manifestations in two cases
10:10FC12.5Teprotumumab in an adolescent with severe corticosteroid-resistant Graves ophthalmopathy: success but unexpected neurological manifestations.
10:20FC12.6TSH screening in premature newborns: a critical appraisal of the value of a second sample.
09:30-10:30Free Communications 13: Pituitary, neuroendocrinology and puberty 2
Chair(s): Cynthia Andoniadou (London, UK) & Anne Rochtus (Leuven, Belgium)
Atlantic
09:30FC13.1Genetic evaluation in children with self-limited pubertal delay discloses new candidate genes
09:40FC13.2Targeted gene panel screening in 144 congenital hypopituitarism patients, incorporating 135 known and novel genes implicated in hypopituitarism and/or hypothalamo-pituitary development.
09:50FC13.3Variants in Methyl-CpG-binding protein 2 (MECP2) are associated with X-Linked Central Precocious Puberty
10:00FC13.4Clinical and molecular genetic characteristics of 98 patients with congenital hypopituitarism: A single-center experience
10:10FC13.5Systematic review and meta-analysis of spermatogenesis rates after pubertal induction with gonadotropins in males with hypogonadotropic hypogonadism
10:20FC13.6Effects of Blue Light Exposure and Exposure Duration on Male Rats Puberty Process
09:30-10:30Free Communications 14 - Late Breaking
Chair(s): Annemarie Verrijn-Stuart (Utrecht, The Netherlands) & Tommaso Aversa (Messina, Italy)
Yangtze 1&2
09:30FC14.1Sleep health characteristics in children with congenital adrenal hyperplasia
09:40FC14.2New Reference Values for Thyroid Volume by Ultrasound in German Children and Adolescents Under Iodine-Sufficient Conditions From a Nationwide Study
09:50FC14.3Deconvolution Analysis: GH secretagogue (LUM-201) enhances growth in individuals with moderate idiopathic Pediatric Growth Hormone Deficiency (iPGHD) by enhancing endogenous GH secretion and increasing IGF-1
10:00FC14.4Improvement in insulin sensitivity and glucose metabolism in adolescents with obesity treated with once-weekly semaglutide 2.4 mg: a secondary analysis of the STEP TEENS trial
10:10FC14.5Predicting Average IGF-I Concentration for Once-Weekly Somapacitan in Children with Growth Hormone Deficiency
10:20FC14.6Understanding the genetic complexity of puberty timing across the allele frequency spectrum
10:30-11:00Refreshment Break, Posters and Exhibition
Exhibition Hall
11:00-11:30Plenary 6
Chair(s): Michel Polak (Paris, France) & Paul van Trotsenburg (Amsterdam, The Netherlands)
King Willem Alexander Auditorium
11:00PL6How the genome predicts human disease
11:30-12:15Awards 4
Chair(s): Anita Hokken-Koelega (Rotterdam, The Netherlands)
King Willem Alexander Auditorium
11:30Andrea Prader Prize (30 mins) + ESPE International Award (15 mins)
12:15-12:45Plenary 7
Chair(s): Nils Krone (Sheffield, UK) & Malgorzata Wasniewska (Messina, Italy)
King Willem Alexander Auditorium
12:15PL7Novel approaches in autoimmune endocrine disorders
12:45-14:15Lunch, posters and exhibition
Exhibition Hall
14:00-14:45Meet the Expert 2.2
Pacific
14:00Informing children about their DSD - when and how?
14:00-14:45Meet the Expert 6.2
Mississippi
14:00Approach to Thyroid cancer in Children
14:00-14:45Meet the Expert 7.2
Yangtze 1&2
14:00Management of hyperinsulism beyond the acute phase
14:15-15:00Novel Advances 2
Chair(s): Daniëlle van der Kaay (Rotterdam, The Netherlands) & Agnes Linglart (Paris, France)
Atlantic
14:15DNA Methylation Episignatures: Defining Biomarkers of Rare Disorders
14:15-15:15Awards - Young Investigators
Chair(s): Martine Cools (Ghent, Belgium)
Amazon
14:15ESPE Young Investigator Awards
14:15Research Unit Lecture
14:15Research Fellowship Lecture
15:10-15:30Refreshment Break, Posters and Exhibition
Exhibition Hall
15:30-17:00Symposium 9 - Thyroid
Chair(s): Athanasia Stoupa (Paris, France) & Christiaan Mooij (Amsterdam, The Netherlands)
Mississippi
15:30S9.1Central hypothyroidism due to mutations in IGSF1 - latest insights into its pathogenesis
16:00S9.2Is there role for combined T4 and T3 therapy in hypothyroidism
16:30S9.3The role of thyroid hormone transporters in brain development and function
15:30-17:00Symposium 10 - Bone
Chair(s): Ola Nilsson (Stockholm, Sweden) & Gabriele Hartmann (Vienna, Austria)
Yangtze 1&2
15:30S10.1Management of Fibrous dysplasia
16:00S10.2Inherited ectopic calcification disorders
16:30S10.3Life-time disease burden of achondroplasia
15:30-17:00Symposium 11 - Diet, nutrients and the environment
Chair(s): Yael Lebenthal (Tel Aviv, Israel) & Edgar van Mil (Venlo, The Netherlands)
Pacific
15:30S11.1Timing of eating and exercise to improve metabolic health in humans
16:00S11.2Sugar and ultra-processed food
16:30S11.3Weight loss and mechanisms of weight regain
15:30-17:00Symposium 12: What's new for the HPG Axis
Chair(s): Sasha Howard (London, UK) & Anne Simone Parent (Liege, Belgium)
Atlantic
15:30S12.1Minipuberty - Looking into the future
16:00S12.2SEMA6A drives GnRH neuron-dependent puberty onset by tuning median eminence vascular permeability.
16:30S12.3Recent advances in our understanding of the regulation of GnRH secretion
17:05-17:35Plenary 8
Chair(s): Indi Banerjee (Manchester, UK) & Tadej Battelino (Ljubljana, Slovenia)
King Willem Alexander Auditorium
17:05PL8Real world use of closed loop insulin delivery
17:35-17:50Awards 5 - ESPE Meeting Host Poster Awards
Chair(s): Paul van Trotsenburg (Amsterdam, The Netherlands)
King Willem Alexander Auditorium
17:55-18:10Closing Ceremony
King Willem Alexander Auditorium